06:28:25 EST Tue 07 Dec 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Opsens Inc
Symbol OPS
Shares Issued 90,599,942
Close 2021-02-25 C$ 1.71
Recent Sedar Documents

Opsens closes $28.75M bought deal offering

2021-02-25 12:34 ET - News Release

Mr. Louis Laflamme reports

OPSENS ANNOUNCES CLOSING OF $28.75 MILLION BOUGHT DEAL PUBLIC OFFERING INCLUDING $3.75 MILLION OVER-ALLOTMENT OPTION EXERCISED IN FULL

Opsens Inc. has closed its previously announced bought deal public offering of common shares of the company for total gross proceeds of approximately $28.75-million. The company issued an aggregate of 15,972,222 common shares, at a price of $1.80 per common share, including 2,083,333 common shares issued pursuant to the exercise in full of the underwriters' overallotment option.

The offering was conducted by a syndicate of underwriters led by Stifel GMP as sole bookrunner and lead underwriter, and including Paradigm Capital Inc., Raymond James Ltd., RBC Dominion Securities Inc. and M Partners Inc.

The company intends to use the net proceeds of the offering: (i) to execute its commercialization and marketing strategy; (ii) to finance research and product development; (iii) to secure additional manufacturing capacity for its coronary artery stenosis products, its structural heart products, its fibre optic sensors and signal conditioners; and (iv) for general working capital purposes.

The common shares were offered by way of a short form prospectus dated Feb. 19, 2021, and filed in all of the provinces of Canada pursuant to Regulation 44-101 respecting short form prospectus distributions (National Instrument 44-101, Short Form Prospectus Distributions outside of Quebec) and in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended.

About Opsens Inc.

Opsens focuses mainly on coronary artery stenosis measurement in interventional cardiology. The company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fibre optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, Japan and Canada.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.